NCT07262632 Developing a Multimodal Cancer Pain Database to Support AI-Based Automatic Pain Assessment
| NCT ID | NCT07262632 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Mark Mulder |
| Condition | Cancer-related Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-12-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to collect short video and sound recordings of people with cancer to create a secure database that can be used in future research to develop an artificial intelligence (AI) tool for pain assessment. The main aim is to build a large, high-quality collection of audiovisual data showing how people with cancer express themselves when they do and do not have pain. Participants will include adults with cancer who are admitted to the oncology ward for pain treatment and a control group admitted for chemotherapy who have no pain. After giving consent, participants will: * Be recorded on video (from the shoulders up) for up to 60 seconds while reading a short sentence and describing their pain or daily experience. * Complete a short questionnaire about their mood and pain expression. * Allow researchers to collect some information from their medical record, such as their pain score, medications, and cancer type. These recordings will be securely stored and used to create a database for future AI research. No medical tests, new treatments, or extra hospital visits are involved. This study will provide the foundation for developing future AI-based tools that could support doctors and patients in monitoring and managing pain more accurately and easily.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥18 years) * Diagnosed with cancer, active * Able to communicate verbally in Dutch or English * Able to provide written informed consent. * Pain group specific: * Experiencing pain related to cancer * Admitted to the hospital due to pain * Control group specific: * Not experiencing pain (NRS = 0) * Admitted to the hospital for chemotherapy Exclusion Criteria: * Cognitive, physical, or medical limitations that prevent participation in the audiovisual recording sessions or affect facial expressions or voice (e.g. facial paralysis, tracheostomy, severe speech impairment). * Critical illness or end-of-life care where participation would impose an additional burden. * Experiencing pain not associated with cancer * Infectious isolation precautions that prevent safe data collection
Contact & Investigator
Mark Mulder, dr.ir.
PRINCIPAL INVESTIGATOR
Erasmus University Medical Centre
Frequently Asked Questions
Who can join the NCT07262632 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer-related Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07262632 currently recruiting?
Yes, NCT07262632 is actively recruiting participants. Contact the research team at m.kamsteeg@erasmusmc.nl for enrollment information.
Where is the NCT07262632 trial being conducted?
This trial is being conducted at Rotterdam, Netherlands.
Who is sponsoring the NCT07262632 clinical trial?
NCT07262632 is sponsored by Dr. Mark Mulder. The principal investigator is Mark Mulder, dr.ir. at Erasmus University Medical Centre. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.